https://scholars.lib.ntu.edu.tw/handle/123456789/503524
標題: | Differential impact of resistance-associated mutations to protease inhibitors and nonnucleoside reverse transcriptase inhibitors on HIV-1 replication capacity | 作者: | SZU-MIN HSIEH SUNG-CHING PAN SUI-YUAN CHANG CHIEN-CHING HUNG WANG-HUEI SHENG Chen M.-Y. SHAN-CHWEN CHANG |
公開日期: | 2013 | 卷: | 29 | 期: | 8 | 起(迄)頁: | 1117-1122 | 來源出版物: | AIDS Research and Human Retroviruses | 摘要: | The effects of drug resistance on HIV-1 replication capacity have been studied, but data from clinical isolates are few. We accessed the patients with HIV-1 infection at the National Taiwan University Hospital who experienced virological failure. Genotypic susceptibility and replication capacity of clinical HIV-1 isolates were measured. There were 80 patients enrolled between September 2007 and August 2010. The HIV-1 replication capacity declined significantly with the increasing number of major resistance-associated mutations (RAMs) to protease inhibitors (PIs) (p<0.001); however, it did not decline significantly with the increasing RAMs to first-line nonnucleoside analogue reverse transcriptase inhibitors (NNRTIs) (p=0.098). Regarding the effects of resistance to antiretroviral drugs in salvage therapy, decreased replication capacity was noted with the increasing RAMs to darunavir/ritonavir (p<0.001) and specific RAMs (L100I, K101P, and Y181C/I/V) to etravirine (p<0.001). Although NNRTI-related RAMs have less remarkable effects, both PI- and NNRTI-related RAMs reduced replication capacity, especially RAMs to darunavir/ritonavir and etravirine, which are commonly used in salvage therapy for treatment of patients infected with highly resistant HIV. Thus, decreased viral fitness during the emergence of RAMs suggests the importance of continued optimal antiretroviral treatment even when virological failure was noted. ? Copyright 2013, Mary Ann Liebert, Inc. 2013. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/503524 | ISSN: | 0889-2229 | DOI: | 10.1089/aid.2013.0038 | SDG/關鍵字: | darunavir plus ritonavir; etravirine; nonnucleoside reverse transcriptase inhibitor; proteinase inhibitor; adult; antiviral resistance; antiviral therapy; article; clinical article; female; gene mutation; genetic susceptibility; human; Human immunodeficiency virus 1; Human immunodeficiency virus 1 infection; male; nonhuman; priority journal; salvage therapy; virus replication; Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Salvage Therapy; Taiwan; Virus Replication |
顯示於: | 醫學檢驗暨生物技術學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。